Msd K.k.

Banyu Pharmaceutical Co. Ltd

Noriaki Hashimoto

Teruyuki Nishimura

Keiji Takahashi

Jun-ichi Eiki

Tomoharu Iino

Hiroshi Nakashima

Chisato Nakama

Yasuhiro Sasaki

Makoto Ishikawa

Yoshio Ogino

Masanori Asai

Yufu Sagara

Fumiko Sakai

Jun-Ichi Eiki

The present invention relates to a compound represented by formula (I), which has a GPR120 agonist action and thus is useful for treatment of diabetes mellitus or hyperlipidemia, or a pharmaceutically acceptable salt thereof. In the formula, (AA) represents a phenyl or the like, which may be substituted with a lower alkoxy group or the like; (BB) represents a divalent group or the like, derived by removal of two hydrogen atoms from a benzene which may be substituted with a halogen atom or the like; X represents a spacer having a main chain composed of 1-8 carbon atoms wherein 1-3 carbon atoms in the main chain may be substituted with an oxygen atom or the like; and Y represents a hydrogen atom or the like.

Phenyl-isoxazol-3-ol derivative

Compounds of a formula (I) and their pharmaceutically-acceptable salts are disclosed. The compounds have glucokinase-activating effect and are therefore useful for treatment of diabetes and obesity.  Rand Reach independently represent a lower alkyl group; Xrepresent a group of a formula (II-1): wherein:Rand Reach independently represent a hydrogen atom or a lower alkyl group, or taken together with the nitrogen atom to which they bond, Rand Rmay form a 4- to 7-membered nitrogen-containing aliphatic ring (one carbon atom constituting the 4- to 7-membered nitrogen-containing aliphatic ring may be replaced by an oxygen atom), or taken together with a carbon atom in (CH), Rand Rmay form a 4- to 7-membered nitrogen-containing aliphatic ring; m indicates an integer of from 1 to 3.

2-pyridinecarboxamide derivative having GK-activating effect

A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein Rand Rrepresent a hydrogen, etc.; Rrepresents a hydrogen atom, a halogen atom, etc.; Reach independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); Rand Reach represent a hydrogen atom, a lower alkyl group, etc.; X, X, Xand Xeach independently represent a carbon atom or a nitrogen atom; Z represents an oxygen atom, a sulfur atom or a nitrogen atom; Ar represents an aryl or heteroaryl group optionally mono to tri-substituted with a group selected from the substituent group &#x3b2;; ring A represents a 5- or 6-membered nitrogen-containing heteroaromatic group; m indicates an integer of from 1 to 6; n indicates an integer of from 0 to 3; p indicates an integer of from 0 to 2 (provided that at least two of Xto Xare carbon atoms); q indicates 0 or 1] or its pharmaceutically-acceptable salt, which has an effect of glucokinase activation and is useful as a treatment for diabetes.

Aryloxy-substituted benzimidazole derivatives

Compounds having glucokinase activating effects and being useful as treatments for diabetes, which are represented by the following formula (I): [wherein Xrepresents oxygen, etc., Xrepresents oxygen, etc., Rrepresents a group on Ring A such as alkylsulfonyl, etc., Rrepresents C3-7 cyclic alkyl optionally substituted with a halogen, etc., Rrepresents a substituent on Ring B such as lower alkyl, etc., formula (II):[Chemical Formula 1] represents 6- to 10-membered aryl, etc., and formula (III):[Formula 1] represents monocyclic or bicyclic heteroaryl optionally having on Ring B a substituent represented by Rabove, wherein the carbon atom of Ring B which is bonded to the nitrogen atom of the amide group of formula (I) forms a C&#x2550;N bond with the nitrogen atom of the ring],as well as their pharmaceutically acceptable salts.

Heteroarylcarbamoylbenzene derivatives

Compounds represented by formula (I): as well as their pharmaceutically acceptable salts are disclosed. The compounds are useful as glucokinase activating agents for the treatment of diabetes and related conditions. Compositions and methods of treatment are also included.

Heteroarylcarbamoylbenzene derivative

Growing community of inventors

Tsukuba, Japan

Noriaki Hashimoto